Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 17/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6607269 | 0.98 | CHRM4 (0.74) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| Acetic Acid SCHEMBL4032699 | 0.91 | CHRM1 (0.70) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL23370707 | 0.89 | CHRM4 (0.74) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6916078 | 0.89 | CHRM1 (0.74) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL7900811 | 0.85 | CHRM4 (0.97) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6913185 | 0.85 | CHRM1 (1.00) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6914130 | 0.85 | CHRM4 (0.69) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL12043378 | 0.84 | CHRM4 (0.67) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL4035543 | 0.84 | CHRM1 (1.00) | CHRM4CHRM1CHRM2CHRM5CHRM3 | |
| SCHEMBL6915575 | 0.84 | CHRM4 (0.67) | CHRM4CHRM1CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355646-B1 | MUSCARINIC RECEPTOR AGONISTS | UNIV TOLEDO (US) | 2009-05-13 | — | — | EP | disclosed |
| US-6602891-B2 | Muscarinic receptor agonists | THE UNIVERSITY OF TOLEDO | 2003-08-05 | — | — | US | disclosed |
| US-20030032658-A1 | Muscarinic receptor agonists | MESSER WILLIAM S (US) | 2003-02-13 | — | — | US | disclosed |
| US-6376675-B2 | PYRIDYL-1,2,5-THIADIAZOLE DERIVATIVES | THE UNIVERSITY OF TOLEDO | 2002-04-23 | — | — | US | disclosed |
| US-20010036953-A1 | Pyridyl-1,2,5-thiadiazole derivatives | TOLEDO, THE UNIVERSITY OF | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032658-A1 | Muscarinic receptor agonists | CHRM3, CHRM4, CHRM2 | CHRM4 2/4885CHRM1 6/4885CHRM2 3/4885 |
| US-20010036953-A1 | Pyridyl-1,2,5-thiadiazole derivatives | CHRM3, CHRNA3, CHRNA2 | CHRM4 6/4885CHRM1 10/4885CHRM2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.